Published in J Am Coll Cardiol on December 29, 2006
Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol (2009) 4.16
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail (2010) 3.01
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol (2009) 2.34
Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. J Am Coll Cardiol (2011) 2.26
Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J (2014) 1.90
Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol (1985) (2008) 1.87
Shortening of the elastic tandem immunoglobulin segment of titin leads to diastolic dysfunction. Circulation (2013) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation (2011) 1.78
Ventricular-vascular interaction in heart failure. Heart Fail Clin (2008) 1.67
Left atrial structure and function and clinical outcomes in the general population. Eur Heart J (2012) 1.64
Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation (2010) 1.62
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J (2008) 1.56
Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study. JACC Heart Fail (2014) 1.54
Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. Circ Cardiovasc Imaging (2016) 1.52
Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation (2013) 1.48
Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2010) 1.46
Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail (2010) 1.38
Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol (2008) 1.34
Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol (2013) 1.34
Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail (2013) 1.33
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25
Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study. J Am Coll Cardiol (2012) 1.12
The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep (2013) 1.11
Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risk Rep (2011) 1.10
Novel echocardiographic techniques to assess left atrial size, anatomy and function. Cardiovasc Ultrasound (2012) 1.10
The sex-specific impact of systolic hypertension and systolic blood pressure on arterial-ventricular coupling at rest and during exercise. Am J Physiol Heart Circ Physiol (2008) 1.08
Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail (2014) 1.07
Heart failure with preserved ejection fraction in the elderly: scope of the problem. Heart Fail Rev (2012) 1.04
Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension (2012) 1.04
Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis (2013) 0.98
Invasive hemodynamic assessment in heart failure. Heart Fail Clin (2009) 0.95
Decreased cardiac functional reserve in heart failure with preserved systolic function. J Card Fail (2010) 0.95
Heart failure with preserved ejection fraction. Glob Cardiol Sci Pract (2012) 0.94
Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93
The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. J Card Fail (2009) 0.91
Diagnosis and assessment of pulmonary vascular disease by Doppler echocardiography. Pulm Circ (2011) 0.88
Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction. Cardiovasc Res (2010) 0.88
Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J (2016) 0.87
Population-based approaches to understanding disparities in cardiovascular disease risk in the United States. Int J Gen Med (2014) 0.87
Heart failure with a normal ejection fraction (HFNEF): embracing complexity. J Card Fail (2009) 0.86
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. Heart Fail Rev (2015) 0.84
Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol (1985) (2015) 0.83
Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail (2014) 0.83
Hemodynamic and arterial stiffness differences between African-Americans and Caucasians after maximal exercise. Am J Physiol Heart Circ Physiol (2013) 0.82
Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity. Hypertension (2010) 0.82
Heart failure with preserved ejection fraction. Pflugers Arch (2014) 0.82
Prognostic utility of right atrial emptying fractions in pulmonary arterial hypertension. Pulm Circ (2015) 0.81
Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag (2016) 0.80
Heart failure with preserved ejection fraction failure to preserve, failure of reserve, and failure on the compliance curve. J Am Coll Cardiol (2009) 0.80
Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev (2013) 0.80
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.79
Ventricular remodeling in heart failure with preserved ejection fraction. Curr Heart Fail Rep (2013) 0.79
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail (2016) 0.79
Ventricular-Arterial Function and Coupling in the Adult Fontan Circulation. J Am Heart Assoc (2016) 0.79
Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. J Geriatr Cardiol (2015) 0.78
Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev (2015) 0.77
Percutaneous Pericardial Resection: A Novel Potential Treatment for Heart Failure With Preserved Ejection Fraction. Circ Heart Fail (2017) 0.77
Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. Curr Cardiol Rev (2015) 0.77
Quantitative assessment of atrial conduit function: a new index of diastolic dysfunction. Clin Res Cardiol (2015) 0.76
Correlation of arterial blood pressure and compliance with left ventricular structure and function in the very elderly. J Am Soc Hypertens (2012) 0.76
Left-ventricular power-to-mass ratio at peak exercise predicts mortality, heart failure, and cardiovascular events in patients with stable coronary artery disease: data from the Heart and Soul Study. Cardiology (2009) 0.76
Evaluation of docosahexaenoic acid in a dog model of hypertension induced left ventricular hypertrophy. J Cardiovasc Transl Res (2013) 0.76
Left atrial strain: a new parameter for assessment of left ventricular filling pressure. Heart Fail Rev (2016) 0.75
Sex Differences in the Associations of Hemodynamic Load With Left Ventricular Hypertrophy and Concentric Remodeling. Am J Hypertens (2015) 0.75
Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction. Circ Heart Fail (2016) 0.75
Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review. Br J Clin Pharmacol (2011) 0.75
Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (TtnΔIAjxn). Circ Res (2016) 0.75
Left Atrial Structure in Relationship to Age, Sex, Ethnicity, and Cardiovascular Risk Factors: MESA (Multi-Ethnic Study of Atherosclerosis). Circ Cardiovasc Imaging (2017) 0.75
Age- and sex-related differences in diastolic function and cardiac dimensions in a hypertensive population. ESC Heart Fail (2016) 0.75
An observational study of the association among interatrial adiposity by computed tomography measure, insulin resistance, and left atrial electromechanical disturbances in heart failure. Medicine (Baltimore) (2016) 0.75
Differential Post-Exercise Blood Pressure Responses between Blacks and Caucasians. PLoS One (2016) 0.75
Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson (2016) 0.75
Heart failure with a normal ejection fraction: treatments for a complex syndrome? Curr Treat Options Cardiovasc Med (2012) 0.75
Left and Right Ventricular Functional Dynamics Determined by Echocardiograms Before and After Lung Transplantation. Am J Cardiol (2015) 0.75
The association among MDCT-derived three-dimensional visceral adiposities on cardiac diastology and dyssynchrony in asymptomatic population. BMC Cardiovasc Disord (2015) 0.75
Treatment strategies for the prevention of heart failure. Curr Heart Fail Rep (2013) 0.75
Human heart failure with preserved ejection versus feline cardiomyopathy: what can we learn from both veterinary and human medicine? Heart Fail Rev (2017) 0.75
Heart Failure with Preserved Ejection Fraction in Older Adults. Heart Fail Clin (2017) 0.75
Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations. J Cardiovasc Transl Res (2017) 0.75
Effects of supervised exercise and dietary nitrate in older adults with controlled hypertension and/or heart failure with preserved ejection fraction. Nitric Oxide (2017) 0.75
Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne) (2017) 0.75
Einstein, the Blind Men, and the Elephant: Making Sense of Heart Failure With Preserved Ejection Fraction. J Card Fail (2016) 0.75
Ventricular-Arterial Coupling in Chronic Heart Failure. Card Fail Rev (2017) 0.75
Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol (2017) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet (2006) 8.19
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr (2008) 7.91
Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation (2005) 6.89
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
beta-Adrenergic stimulation modulates ryanodine receptor Ca(2+) release during diastolic depolarization to accelerate pacemaker activity in rabbit sinoatrial nodal cells. Circ Res (2002) 4.66
Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation (2005) 4.61
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med (2004) 4.50
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol (2009) 4.16
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Superoxide flashes in single mitochondria. Cell (2008) 4.08
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med (2006) 3.59
Arterial aging: is it an immutable cardiovascular risk factor? Hypertension (2005) 3.55
Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens (2009) 3.47
High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells. Circ Res (2006) 3.42
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation (2013) 3.28
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
AGEMAP: a gene expression database for aging in mice. PLoS Genet (2007) 3.22
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet (2007) 3.21
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol (2004) 2.91
Synergism of coupled subsarcolemmal Ca2+ clocks and sarcolemmal voltage clocks confers robust and flexible pacemaker function in a novel pacemaker cell model. Am J Physiol Heart Circ Physiol (2009) 2.89
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
Derivation and validation of diagnostic thresholds for central blood pressure measurements based on long-term cardiovascular risks. J Am Coll Cardiol (2013) 2.79
Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol (2008) 2.75
Sex differences in arterial stiffness and ventricular-arterial interactions. J Am Coll Cardiol (2012) 2.74
Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation (2009) 2.70
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension (2006) 2.64
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension (2007) 2.42
Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol (2012) 2.41
Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol (1985) (2008) 2.40
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke (2009) 2.28
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail (2012) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Calcium cycling protein density and functional importance to automaticity of isolated sinoatrial nodal cells are independent of cell size. Circ Res (2007) 2.17
A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr (2007) 2.16
Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension (2013) 2.15
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women. J Hypertens (2003) 2.04
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension (2015) 2.01
Long-term changes in serum cholesterol level does not influence the progression of coronary calcification. Int J Cardiol (2010) 1.99
White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol (2007) 1.98
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Ca2+/calmodulin kinase II-dependent phosphorylation of ryanodine receptors suppresses Ca2+ sparks and Ca2+ waves in cardiac myocytes. Circ Res (2007) 1.98
HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant (2013) 1.96
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92